Gender effects have been reported quite consistently in schizophrenia, with male patients having an earlier age of onset, poorer functional outcome, greater negative symptoms and cognitive impairment, and less severe positive symptoms. Because age of onset, cognitive impairments, and negative symptoms are all correlated with poorer functional status, it is not clear if previously reported gender differences in symptoms are just recapturing gender differences in functional outcome. In this study, 205 geriatric patients with lifelong poor-outcome schizophrenia (43% male) were examined for the severity of schizophrenic symptoms, cognitive impairments, and specific deficits in adaptive skills, as well as for demographic differences such as age at first psychiatric admission, premorbid education, and current treatment status. Previously reported gender differences were replicated in these patients with a uniformly poor functional outcome, with male patients having more severe negative symptoms and an earlier age of first psychiatric admission. No differences in cognitive functioning or specific functional deficits were found, however. These findings suggest that negative symptom severity is greater in male patients regardless of functional outcome and that the association of cognitive deficits with gender may be found only in patients with better functional outcome. The study of gender-related differences in brain structure or function and their interaction with overall course of illness might help understand these differences in symptom presentation.
Gender differences in schizophrenia have received considerable attention in recent years. Gender differences have been found in age of onset, symptomatology, course of illness, treatment response, cognitive functioning, and social and adaptive functioning. Previous research has consistently indicated that female patients have a later age of onset, fewer negative symptoms, better premorbid social functioning, less extensive cognitive impairment, and a better overall functional outcome than male patients. These gender differences may provide important information about potential sex differences in brain functioning in patients with schizophrenia.
The majority of studies suggest that males have an earlier age at first hospitalization (Chu et al. 1989; Goldstein et al. 1989; Hafner et al. 1989; Hafner et al. 1995; Larsen et al. 1996) . The differences in age at first hospitalization have ranged from two to six years. Other research has suggested a general shift in onset age between male and female patients, with female patients being much more likely to have a later onset of symptoms regardless of when hospitalization first occurred. In a large-scale population-based prospective study, Castle and Murray (1993) examined the new-onset cases of schizophrenia in a London borough. They found that the average age of onset for males (31.2) was 10 years younger than that of females (41.1). The male/female ratio changed as a function of age of onset, with the ratio at 1.6/1 for onset from age 16 to 25 and 0.2/1 for onset age in late life. Using family ratings of the first appearance of schizophrenic symptoms, males still show an earlier symptom onset than females (Jayaswal et al. 1987; Gureje 1991; Faraone et al. 1994) . Age of onset differences may also be related to familial versus nonfamilial status. Albus and Maier (1995) found no difference in age at onset in familial cases of schizophrenia (38 male-male pairs, 29 female-female pairs, and 39 mixed gender pairs) but an earlier age at onset for males in nonfamilial cases. Andia et al. (1995) found that women had a higher level of premorbid functioning, including both greater educational attainment and a greater likelihood of being married prior to onset of the illness. Women have been reported to be more likely to initially present with comorbid depression or anxiety disorders, whereas men are more likely to receive a diagnosis of substance abuse or alcohol abuse, and to have difficulty in impulse control at the time of first psychiatric admission (Fabrega et al. 1990) . The majority of studies report that men tend to experience more affective flattening and negative symptoms at the time of the first episode as compared to females (Haas and Sweeney 1992) . In an archival study, Walker et al. (1985) found that female patients scored higher on factors defined by nonblunted affective symptoms, such as depression and suicidal tendencies. Furthermore, Szymanski et al. (1995) found that female first-episode schizophrenia patients had significantly less illogical thinking but more anxiety, inappropriate affect, and bizarre behavior when compared to male patients. In contrast, Mueser et al. (1990) found no gender differences in symptomatology. Female patients were found in that study to show higher degrees of social competence after the onset of illness, as compared to males (Mueser et al. 1990) , with this difference stable over the year following an index psychiatric admission.
Premorbid social functioning has also been found to be correlated with long-term outcome in males and females. Women tend to show better premorbid social functioning (Childers and Harding 1990) and the social adjustment of male patients deteriorates at a faster rate after the development of the illness (Larsen et al. 1996) . In a three-year followup of first-admission schizophrenia patients, females experienced fewer readmissions and shorter lengths of stay after readmission, and survived longer in the community without symptom exacerbation (Angermeyer et al. 1989) . Goldstein (1988) found similar results in a 10-year followup study, with women having fewer rehospitalizations and shorter lengths of stay if admitted.
Another critical area in schizophrenia-related gender differences is that of cognitive functioning. Perlick et al. (1992) reported that when using the Dementia Rating Scale as a dependent measure, female schizophrenia subjects showed greater impairment on Attention and Conceptualization than male schizophrenia subjects. Some studies found that male schizophrenia subjects had more impairment on neuropsychological tests of verbal learning and verbal fluency (Hoff et al. 1991) , as well as more structural brain abnormalities (Andreasen 1986; Josiassen et al. 1990; Lewine et al. 1990 ). Lewine et al. (1997) found an interaction between gender and onset age in neurocognitive impairment. Among patients with an early onset, males were more impaired, while among lateonset patients, females were more impaired.
The present study investigated geriatric differences in poor-outcome schizophrenia patients, comparing them across gender on clinical symptoms and cognitive functioning. The purpose of this research was to determine whether gender differences are preserved in poor-outcome schizophrenia patients who have had a lifelong course of chronic institutionalization. Although these patients do not represent the majority of patients with schizophrenia, they represent an important subgroup. This subgroup of patients has the highest cost of care and the greatest risk for cognitive and functional decline in late life (Harvey et al. 1999a; Harvey et al. 1999fc) . They also represent a group in which the level of overall functional deficit is extreme and, by definition, consistent across gender. If chronic institutional care and a long history of somatic treatment influence the cognitive, symptomatic, or functional presentation of patients with schizophrenia, then gender differences should be reduced in this sample.
In addition, since poor functional outcome is a constant in this sample, gender differences in overall functional outcome would be expected to be restricted. Since female patients tend to have a better overall functional outcome than male patients, previous findings of reduced levels of cognitive and negative symptoms in females could result from the fact that these symptoms are correlated in general with overall functional outcome status (Green 1996) . In this sample with poor functional outcome as a constant, previous findings of gender-related differences in negative symptoms and cognitive functioning in better-outcome patients could be examined in a context where global functional outcome is the same. In this sample, therefore, any gender differences in symptoms, cognitive functions, or specific adaptive skills would not be due to gender-related differences in outcome status.
In our previous research with poor-outcome patients, we have used this strategy to dissociate the classically reported differences between affective disorder and schizophrenia (Harvey et al. 1997c) . In that study, we found that mood-disordered patients with an extended institutional stay were as cognitively impaired as poor-outcome schizophrenia patients. These findings suggest that previous reports of global differences in performance between patients with these illnesses (Goldberg et al. 1993 ) could be related to overall differences in functional outcome between affective and schizophrenia patients. In Harvey et al. (1997c) affective disorder and schizophrenia patients manifested very different symptom profiles, indicating that cognitive impairment was related to outcome more strongly than outcome was related to illness-specific symptoms of affective disorder and schizophrenia. Thus, we hypothesize that gender differences in poor-outcome patients would be limited to onset age and symptom vari-ables and not to neurocognitive functioning. This hypothesis is based on our previous finding that patients with affective disorder and patients with schizophrenia who shared a poor functional outcome had similar cognitive functioning in the context of dissimilar symptom profiles. In terms of the symptom variables, we hypothesized that male patients would have more severe negative symptoms, less severe positive symptoms, and more severe deficits in specific adaptive skills than female patients. Based on the results of our previous research examining the relationship between adaptive and cognitive functioning in good-outcome versus poor-outcome patients with schizophrenia (Harvey et al. 1998) , we expected the correlation between cognitive and adaptive deficits to be the same in male and female patients, despite expected gender differences in the severity of symptom variables. We tested this hypothesis, singly and in the context of an evaluation of overall differences in symptom structure between the genders.
Methods
Subjects. All patients were participants in a large-scale research program on cognitive functioning and clinical symptoms in geriatric chronic psychiatric inpatients. In this study, the entire long-stay population of a state psychiatric center was rediagnosed and re-evaluated with a comprehensive assessment of clinical, cognitive, and functional status. At the time of entry into the study, all patients had been continuously institutionalized for at least 10 years. Diagnostic assessments were performed by research staff members and a structured consensus procedure was employed in order to generate DSM-III-R (APA 1987) diagnoses of schizophrenia. The entire assessment procedure for that study has been published and all subjects in this study were diagnosed and assessed with that procedure Davidson et al. 1996) . Patients were excluded at the current or previous assessment for the presence of any disorders that ruled out DSM-III-R schizophrenia, including mental retardation, substance dependence, neurological diseases or damage, and other psychiatric diagnoses. Patients with a lifetime history of substance dependence or with evidence of rapid cognitive decline in the past year (on the basis of clinical impression by a neurologist at an annual examination) were excluded, as were patients with hospital-chart evidence of head trauma with loss of consciousness or disease of the central nervous system. Diseases that led to exclusion included seizure disorders, brain tumors, history of stroke or definite vascular pathology, and a possible or definite diagnosis of a degenerative condition such as multiple sclerosis, Pick's disease, or Alzheimer's disease. Patients who had been uncooperative with any aspects of the assessment or testing or who had a MiniMental State Examination (MMSE; Folstein et al. 1975 ) score of 0 were excluded at the initial or followup assessments. The subjects in this study consisted of the remainder of the initial sample of subjects who were still in the hospital at the second assessment. The second assessment was chosen because the comprehensive assessment of social and self-care functions used in this study was not completed on all patients at the baseline assessment.
There were 89 male patients and 116 female patients in the sample of 205 subjects that we examined. Information regarding demographic characteristics was collected from hospital charts and from interviews with the patients in order to allow for analyses of gender effects on these variables. All would have met criteria for "Kraepelinian" poor-outcome status as described in our previous studies of younger poor-outcome patients (e.g., Keefe et al. 1987 Keefe et al. , 1996 Davis et al. 1998 ). Descriptive information on the patients is presented in table 1.
Assessments
Negative and positive symptoms. Severity of schizophrenic symptoms was assessed using the Positive and Negative Syndrome Scale (PANSS; Kay 1991). This is a 30-item scale with 7 items measuring positive symptoms, 7 measuring negative symptoms, and 16 items measuring general aspects of psychopathology. In this study, we used the item scores on all items as our dependent measures.
Interrater reliability of these ratings in our patients was previously found to be acceptably high, with Intra Class Correlations in -30) ranging from a low of 0.86 to a high of 1.00 (all ps< 0.001).
Cognitive functioning. In this study we used both global and specific measures of cognitive functioning. We used the MMSE as a global measure of cognitive functioning, and the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) cognitive battery as a measure of several specific aspects of cognitive functioning that are impaired in both patients with lifelong chronic schizophrenia and those with dementia (Davidson et al. 1996) .
The MMSE is reliable in this population, on interrater (ICC = 0.99, n = 35, Harvey et al. 1992 ) and one-month test-retest (ICC = 0.90, n = 50, Harvey et al. 1995 ) levels, as well as stable over time (ICC = 0.88 at 1 year, n = 224, Harvey et al. 1995) . MMSE scores range from 0 to 30 and comprise the results of an assessment of registration, memory, orientation, praxis, and verbal skills such as naming.
The CERAD cognitive battery is a brief neuropsychological assessment developed for the diagnosis and staging of Alzheimer's disease (Morris et al. 1989) . As a result, it measures several crucial cognitive impairments that are present in dementia. Our previous research with this battery has demonstrated that Alzheimer's patients can be discriminated from patients with schizophrenia on a cross-sectional basis (Davidson et al. 1996) . Additional studies with the CERAD battery demonstrated that schizophrenia patients have high test-retest stability coefficients and do not decline as a group at a 1-year followup on any of the measures in the battery (Harvey et al. 1996&) . In previous analyses of the performance of geriatric patients with schizophrenia on this battery (Harvey et al. 1997d; Harvey et al. 1998) , we have developed a composite measure of cognitive functioning, which was created by standardizing all of the scores within the sample of schizophrenia patients and averaging them into a single score.
The CERAD battery includes four assessments: word list learning and delayed recall, praxic drawings, the Modified Boston Naming Test, and category fluency.
Adaptive functioning. The Social Adaptive
Functioning Evaluation (SAFE) is a 17-item scale developed by the current investigators ) to measure social-interpersonal, instrumental, and impulsecontrol dimensions. This scale is designed to be rated by an observer after observation of the patient, personal interaction with the patient, and an interview with the primary caregiver. Previous research with this scale found that both social and instrumental skills deficits were found to be related to cognitive impairments, while deficits on the impulse control subscale were not (Harvey et al. \991d) . This scale has suitable reliability, with interrater reliabilities of the items all exceeding 0.88 (ICC, n = 60). The total score and the three subscale scores are the key dependent measures.
Results
Demographic Characteristics. Descriptive characteristics of the patients are presented in table 1. Age, age at onset, and years of education were compared across the two samples with t tests. All patients were receiving treatment with conventional antipsychotic medication at the time of this assessment. The samples did not differ significantly with respect to age (t = 1.11, df = 203, p = 0.27). The groups also did not differ significantly with respect to level of education completed (t = -1.13, df = 203, p = 0.26). Male patients were found to have a significantly younger age at the time of the first psychiatric hospitalization (t = 2.03, df= 203, p = 0.04). The proportion of male and female patients treated with anticholinergic medication was not different across the groups, % 2 (1) = 1.22, p > 0.10. Clinical Symptoms. Scores on the PANSS symptoms are presented in table 2. All 30 PANSS symptoms were compared across the groups simultaneously with a multivariate analysis of variance (MANOVA). The overall effect was not significant (Wilks X = 0.835, Pillai's Approx F = 0.165, p = 0.285). When individual symptoms were examined with multivariate corrected F tests, male patients were found to be more impaired on blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity/flow of conversation, and active social avoidance, as well as on the negative symptoms total score. Female patients were found to have more severe symptoms in the area of somatic concern. There were no significant gender differences in any of the positive symptoms or in the positive symptom total score.
Cognitive Functioning. Scores on the CERAD cognitive battery and the MMSE are presented in table 3. Again, a MANOVA was employed to examine the group differences. The overall effect was nonsignificant (Wilks X= 0.965, Pillai's Approx F = 0.035, p = 0.420). Male and female patients performed similarly on the cognitive mea- sures, with no differences between the groups found to be significant on the basis of multivariate corrected F tests; univariate F(l,203) < 2.6 and p > 0.10 for all.
Adaptive Functioning. Total and subscale scores on the SAFE scale are presented in table 4. A t test was used to compare the groups on the total score and another MANOVA was employed to examine the gender differences on the three subscales. There were no gender differences on total SAFE scores, t = -0.59 (203), p = 0.556. The overall effect for the MANOVA on the three subscales was nonsignificant (Wilks X = 0.958, Pillai's Approx F = 0.04, p = 0.52). There were no significant differences between men and women on self-care, impulse control, or social skills; univariate F (1,203) < 2.79 andp > 0.10 for all. There was a trend-level difference in social skills deficits, with female patients manifesting reduced impairment.
Correlation Between Adaptive Functioning, Cognitive
Functioning, and Symptom Status. Table 5 presents Pearson correlations between scores on the SAFE scale, the cognitive composite (CERAD), the MMSE, and the PANSS positive and negative scales in the total sample.
As can be seen in the table, the severity of positive symptoms was essentially uncorrelated with negative, cognitive, and functional symptoms. Cognitive and negative symptoms were intercorrelated and both were correlated with the severity of functional deficits. Several tests were computed to examine the structure of symptoms across the genders. In order to test the specific hypothesis of a similar correlation between cognitive and functional status across the genders, the zero-order Pearson correlation between the composite cognitive functioning score and the SAFE scale total score was computed for each gender. For males, this correlation was r = -0.74; for females, the correlation was -0.79. When these correlations were compared with a z test, the difference was found to be nonsignificant (z = 1.01, p = 0.50). Next, a structural equation analysis was performed to examine whether the overall patterns of correlation were similar for both the male and female populations for the cognitive, adaptive functioning, and symptom variables. This analysis tests the null hypothesis that the two matrices are sampled from the same population and a statistically significant result indicates that the two matrices are significantly different from each other. The test statistic is * statistical significance at p < 0.001, two-tailed the chi-square result from the structural equation modeling procedure. The analysis was performed with the EQS version 2.0 program (Bentler and Mooijaart 1989) . The variables entered into the equation were the SAFE scale total score, the PANSS positive and negative subscale scores, and the cognitive functioning composite score. The analysis of similarity of the 4 x 4 correlation matrices in the two samples resulted in a chi-square of 9.189 (df = l,p = 0.239). These results indicate that the overall correlation matrices are essentially identical for the two groups, suggesting no differences in the structure of overall symptomatology for the two samples.
Discussion
This study of gender differences in poor-outcome patients found that these patients were in some ways similar to samples of better-outcome patients previously studied. For example, previously reported gender differences in age of onset and in the severity of certain negative symptoms were still found even in poor-outcome patients with a lengthy history of institutionalization and somatic treatment. In contrast to some of the previous literature, there were no gender differences in cognitive functioning or in specific adaptive skills. The lack of difference in specific adaptive skills is probably not surprising because the patients were selected on the basis of a lifelong course of chronic illness and functional deficit. Thus, these data suggest that age of onset and negative symptom severity are associated with gender regardless of the overall severity of lifetime functional deficit. Similar to our previous finding regarding lack of difference in cognitive functioning in poor-outcome patients with schizophrenia and affective disorders, cognitive impairment was not found to differ across gender. Finally, the overall structure of the symptoms was similar in each gender, as was the correlation between cognitive and functional status, suggesting that the interrelationships between cognitive functions, clinical symptoms, and adaptive deficits were uniform despite some differences in the severity of these symptoms.
The subjects in this sample were particularly cognitively impaired and manifested severe functional deficits that are not typical for all patients with schizophrenia. These patients also have a history of poor premorbid functioning and poor educational attainment, which might affect the current results. The purpose of this study was to examine the characteristics of patients with severe functional deficit, so the results might not apply to elderly patients with a better lifetime functional outcome or to younger patients regardless of functional status. Furthermore, all patients were receiving treatment with conventional antipsychotic medication, which could have influenced the severity of their symptoms and the correlation between these symptoms. As noted above, these patients were selected for particularly poor functional outcome, so differences in specific adaptive skills would be unlikely to be detected. In addition, the lack of cognitive differences might be due to the use of a test battery that is not completely comprehensive. This battery does not assess all of the previously identified cognitive deficits seen in patients with schizophrenia. It should also be noted that there were numerical differences that approached statistical significance in some of the cognitive variables, with female patients performing better on all tests that approached a difference between the groups. Finally, poor premorbid functioning is common in this sample and poor premorbid intellectual attainment may have led to floor effects in the cognitive measures and reduced the likelihood of detecting differences.
The sample contains more females than males, despite the fact that narrowly defined schizophrenia appears more common in males. Two other samples of long-stay patients evaluated in late life were also found to contain more women. Arnold et al. (1995) reported that 56 percent of the patients in their sample of chronically institutionalized patients in Pennsylvania were female. Harvey et al. (1997fo) reported that 70 percent of a sample of long-stay patients in the United Kingdom were female, as compared to 57 percent of the patients in the present study. The age of our sample may lead to differential rate of survival across the genders and thus inflate the number of females. Since cognitive impairment may be a risk factor for mortality, some of the lower-functioning male patients might have been eliminated. Thus, the gender distribution in this study is consistent with previous institutionalized samples, but not necessarily with the overall distribution of elderly patients with schizophrenia in general. Our previous research suggested that gender was not a predictive factor for discharge in late life when other aspects of the illness, such as agitation and physical illness, were considered . The interpretation of these results is aimed only at understanding the characteristics of patients who have particularly poor outcome and a chronic institutional stay, and not at the characteristics of late-life schizophrenia or long-term outcome in general.
Despite the treatment-refractory and chronically institutionalized nature of both the male and female samples, several gender differences were detected. Differences in age of onset were found between male and female patients, replicating the consistent finding of a later age at first admission in female patients (Castle and Murray 1993) . Our female subjects were typically about 2 l / 2 years older than males when they were first admitted to a psychiatric facility. The difference in our sample is somewhat smaller than what has been seen previously, but the average age of first admission for each gender is in the range of what has been cited previously in the literature. An additional factor that could reduce gender differences is that earlier onset is associated with worse overall outcome and the specific sample that we are studying has a particularly poor outcome.
Negative symptom differences across gender were also preserved in this poor-outcome sample. Male subjects displayed significantly more severe negative symptoms than their female counterparts. The only PANSS negative-symptom items that were not significantly worse in males were Difficulty in Abstract Thinking and Stereotyped Thinking. These symptoms could actually be indicators of impairments in cognitive functioning. There were no group differences in positive symptoms. The level of severity of negative symptoms in our female patients is still very high, despite the less severe symptoms than male patients, and the severity of positive symptoms in the entire sample of patients is considerable.
There were no group differences in cognitive functioning. Lewine et al. (1997) previously found that more severe cognitive impairment on .the part of male patients was present only in cases with an early onset and resultant adverse course of illness. Other studies, however, have found that female patients outperform males on measures of cognitive status. Since cognitive impairment is typically found to be related to functional deficit (see Green 1996 for a comprehensive review), the finding of better cognitive functioning in female patients in samples of patients with better-outcome schizophrenia may be related to the generally higher level of adaptive functioning on the part of female patients. In this sample, where functional outcome was a constant across gender, negative symptoms were found to vary with gender while cognitive functioning did not. Similar results in a younger sample of largely chronic patients were reported by Goldberg et al. (1995) , who found minimal differences between male and female patients even when 100 different cognitive functioning variables were examined. Thus, the lack of gender differences in cognitive functioning may be a general feature of patients with a chronic course of illness regardless of age.
Although negative symptoms are known to relate cross-sectionally (Keefe et al. 1987; Perlick et al. 1992) and longitudinally (Knight et al. 1979) to poor outcome, this study finds that negative symptoms vary by gender within patients with a uniformly poor outcome. The structure of schizophrenic symptoms was the same across gender, regardless of differences in the severity of negative symptoms. Similar to our previous studies of symptom structure in medicated and unmedicated patients (Harvey et al. 1996a) , symptom structure appears preserved across variation in the severity of schizophrenic symptoms. As a result, in our poor-outcome patients, gender was associated with differences in the severity of negative symptoms, but not with differences in the general structure of symptomatology. There are substantial differences in negative symptom severity across gender regardless of the overall level of functional outcome of the patient. Future research should be directed at the identification of possible differences in brain structure or function across gender in schizophrenia, with special reference to negative symptoms.
